Pharma Strategy and Competitive Intelligence

Business intelligence in a biotechnology world

Pharma Strategy and Competitive Intelligence header image 4

Entries Tagged as 'pharma'

Increasing importance of competitive intelligence in bear markets

October 18th, 2008 · No Comments · Market research, biotech, brain cancer, competitive intelligence, marketing, oncology, pharma

In tough economic times, many companies are forced to downsize, trim budgets and preserve profit margins, while expecting a leaner, meaner organisation to survive the tempest. The reality is that the changes leave fewer people to accomplish the same amount of work on less marketing dollars; productivity becomes the new name of the game. This [...]

[Read more →]

Tags:

Procrit linked to deaths in stroke patients

October 1st, 2008 · No Comments · Epoetin alfa, FDA, Food and Drug Administration, competitive intelligence, pharma, strategy

Johnson and Johnson’s Ortho Biotech has informed the FDA of preliminary safety findings from a clinical trial conducted in Germany investigating the use of Procrit (epoetin alfa) to treat acute ischemic stroke. The clinical trial utilised doses of Procrit that were considerably higher than the doses recommended for the treatment of anemia as described in [...]

[Read more →]

Tags:

Abiraterone and prostate cancer

September 2nd, 2008 · No Comments · Cougar, abiraterone, biotechnology, cancer, competitive intelligence, oncology, pharma, prostate, strategy

One drug that has been tearing up the newsfeed this year is abiraterone, a novel drug in phase II trials for prostate cancer. In February, data was presented at ASCO’s Genito-urinary satellite meeting that looked promising. Dr D.C. Danila and researchers from Memorial Sloan Kettering reported a small phase II trial in castration resistant metastatic [...]

[Read more →]

Tags:

Improving survival in Liver Cancer – at what cost?

July 28th, 2008 · No Comments · cancer, competitive intelligence, health, liver cancer, market trends, oncology, pharma, strategy

No effective therapy is available for advanced hepatocellular carcinoma (liver cancer), it’s a terminal condition. Over 18,000 people typically die from it in the USA each year. It is much more common in Africa and East Asia where the risk of infection from Hepatitis B and C is much higher, which are associated with increased [...]

[Read more →]

Tags: